Challenging Treatment of Drug-Resistant Tuberculosis during Pregnancy: A Case Report
Downloads
Introduction: Globally, drug-resistant tuberculosis (TB) still has a high number of cases. Pregnant women are one of the high-risk populations for TB infection, especially multidrug resistance (MDR)/Rifampicin resistance (RR) TB. Physiological differences in pregnant women and the safety of the fetus make drug resistance TB treatment challenging.
Case: A 20-year-old woman was 22 weeks pregnant while undergoing the third month of the late phase for short-regimen. Thus, Kanamycin was one of her early phase treatment combinations during the first trimester of pregnancy. After we consulted with other departments, especially the obstetric department, we decided not to change her regimen. Her chief complaint before treatment was cough with white sputum and fluctuated shortness of breath for two months. The patient only experienced minor side effects in the early treatment phase. The patient was cured of MDR TB on 8 October 2020 at 34 weeks of gestation. Her baby was born on 10 November 2020 at 37 weeks without congenital abnormality. Observation for her baby continued by the pediatric department. The last follow-up of her baby in the middle of 2022 found no abnormality in the child’s growth and development.
Conclusion: Drug-resistant TB therapy in pregnant women requires the collaboration of a multidisciplinary team to consider the benefits and risks of the therapy based on gestational age and disease severity.
World Health Organization (WHO). Surveillance of Drug-Resistant TB. Geneva, https://www.who.int/teams/global-tuberculosis-programme/diagnosis-treatment/treatment-of-drug-resistant-tb/surveillance-of-drug-resistant-tb (2020, accessed October 14, 2020).
Widiasari NPA, Kusumawardani IAJD, Rai IBN. Descriptive Study: Level of Communities Knowledge and Perception about Tuberculosis (TB) in Denpasar, Bali. Respiratory Science 2020; 1: 1–14.
Jonsson J, Kühlmann-Berenzon S, Berggren I, et al. Increased Risk of Active Tuberculosis during Pregnancy and Postpartum: A Register-Based Cohort Study in Sweden. Eur Respir J 2019; 1901886.
Kraus TA, Engel SM, Sperling RS, et al. Characterizing the Pregnancy Immune Phenotype: Results of the Viral Immunity and Pregnancy (VIP) Study. J Clin Immunol 2012; 32: 300–311.
Kementerian Kesehatan Republik Indonesia. Panduan Pelayanan Tuberkulosis Resisten Obat untuk Fasilitas Pelayanan Kesehatan. Jakarta, 2019.
Rohilla M, Joshi B, Jain V, et al. Multidrug-Resistant Tuberculosis during Pregnancy: Two Case Reports and Review of the Literature. Case Rep Obstet Gynecol 2016; 2016: 1–4.
Palacios E, Dallman R, Muñoz M, et al. Drug-Resistant Tuberculosis and Pregnancy: Treatment Outcomes of 38 Cases in Lima, Peru. Clin Infect Dis 2009; 48: 1413–1419.
Yusuf D, Lisnawati Y. Luaran Bayi dari Ibu dengan Tuberkulosis Resistan Multi Obat. Journal of the Indonesian Medical Association; 69. Epub ahead of print October 2, 2019.
Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pelatihan Penanggulangan Tuberkulosis Bagi Petugas Kesehatan di Fasilitas Kesehatan Tingkat Pertama dan Fasilitas Kesehatan Rujukan Tingkat Lanjutan. Jakarta, 2018.
Loto O, Ibraheem A. Tuberculosis in Pregnancy: A Review. J Pregnancy 2012; 2012: 379271.
al Ubaidi BA. The Radiological Diagnosis of Pulmonary Tuberculosis (TB) in Primary Care. J Fam Med Dis Prev; 4. Epub ahead of print January 1, 2018.
Adzani M, Dalimoenthe NZ, Wijaya I. Profile of Anemia on Lung Tuberculosis at Dr. Hasan Sadikin General Hospital and Community Lung Health Center Bandung. Althea Medical Journal 2016; 3: 137–140.
Barzegari S, Afshari M, Movahednia M, et al. Prevalence of Anemia among Patients with Tuberculosis: A Systematic Review and Meta-Analysis. Indian J Tuberc 2019; 66: 299–307.
Ormerod P. Tuberculosis in Pregnancy and the Puerperium. Thorax 2001; 56: 494.
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63: e147–e195.
Bothamley G. Drug Treatment for Tuberculosis during Pregnancy: Safety Considerations. Drug Saf; 24.
Stephanie P, Evelin W, Reinhard M, et al. Observational Cohort Study of Pregnancy Outcome after First-Trimester Exposure to Fluoroquinolones. Antimicrob Agents Chemother 2014; 58: 4392–4398.
Drobac PC, del Castillo H, Sweetland A, et al. Treatment of Multidrug-Resistant Tuberculosis during Pregnancy: Long-Term Follow-Up of 6 Children with Intrauterine Exposure to Second-Line Agents. Clin Infect Dis 2005; 40: 1689–1692.
Shin S, Guerra D, Rich M, et al. Treatment of Multidrug-Resistant Tuberculosis during Pregnancy: A Report of 7 Cases. Clin Infect Dis 2003; 36: 996–1003.
Alaga A, Fairous M, Razul M. MDR TB Treatment of An Expectant Mother – A Case Report. J Lung Health Dis; 4. Epub ahead of print March 13, 2020.
Park WS, Kang HY, Kim SJ. Notified Tuberculosis Status in Korea. Public Health Weekly Report 2015; 9: 342–345.
Yang T-W, Park HO, Jang H, et al. Side Effects Associated with the Treatment of Multidrug-Resistant Tuberculosis at a Tuberculosis Referral Hospital in South Korea: A Retrospective Study. Medicine 2017; 96: e7482.
Amber A, S CG, Min KO, et al. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother 2017; 61: e02586-16.
Mantefardo B, Sisay G. Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen. Int Med Case Rep J 2021; 14: 815.
Holdiness MR. Teratology of the Antituberculosis Drugs. Early Hum Dev 1987; 15: 61–74.
Raphael Y, Fein A, Nebel L. Transplacental Kanamycin Ototoxicity in the Guinea Pig. Arch Otorhinolaryngol 1983; 238: 45–51.
Copyright (c) 2022 Ni Luh Putu Eka Arisanti, Ni Putu Ayu Widiasari, Ni Wayan Candrawati, Ida Ayu Jasminarti Dwi Kusumawardani, Ida Bagus Ngurah Rai, Made Ary Sarasmita
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under “the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (